LGL Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.19M Buy
+1,293
New +$1.31M 0.49% 22
2025
Q1
Sell
-2,027
Closed -$1.56M 88
2024
Q4
$1.56M Buy
2,027
+22
+1% +$18.2K 0.23% 37
2024
Q3
$1.78M Buy
2,005
+20
+1% +$18K 0.25% 32
2024
Q2
$1.8M Buy
1,985
+5
+0.3% +$4K 0.26% 32
2024
Q1
$1.54M Sell
1,980
-277
-12% -$197K 0.26% 35
2023
Q4
$1.32M Hold
2,257
0.18% 39
2023
Q3
$1.21M Hold
2,257
0.21% 39
2023
Q2
$1.06M Hold
2,257
0.18% 40
2023
Q1
$775K Hold
2,257
0.13% 41
2022
Q4
$826K Hold
2,257
0.15% 38
2022
Q3
$730K Hold
2,257
0.15% 40
2022
Q2
$732K Hold
2,257
0.12% 42
2022
Q1
$646K Hold
2,257
0.09% 51
2021
Q4
$623K Hold
2,257
0.07% 56
2021
Q3
$521K Hold
2,257
0.32% 45
2021
Q2
$518K Hold
2,257
0.31% 45
2021
Q1
$422K Hold
2,257
0.24% 53
2020
Q4
$381K Hold
2,257
0.22% 58
2020
Q3
$334K Hold
2,257
0.2% 67
2020
Q2
$371K Hold
2,257
0.23% 60
2020
Q1
$313K Hold
2,257
0.21% 59
2019
Q4
$297K Hold
2,257
0.1% 79
2019
Q3
$252K Hold
2,257
0.1% 92
2019
Q2
$250K Hold
2,257
0.1% 95
2019
Q1
$293K Buy
+2,257
New +$274K 0.11% 84

Other funds holding LLY

LGL Partners's LLY Position: Q1 2026 in Review

LGL Partners opened a new position in Eli Lilly (LLY) in Q1 2026: 1,293 shares worth $1.19M. The stake represents 0.49% of the portfolio and ranks #22 among its holdings. This is a return to the name: LGL Partners previously reported a position in LLY as recently as Q4 2024.

LGL Partners first reported a position in LLY in Q1 2019 and has held it in 25 quarters since. The position peaked at $1.8M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • LGL Partners held 1,293 shares of Eli Lilly worth $1.19M as of Q1 2026.
  • Eli Lilly was a new LGL Partners position in Q1 2026.
  • Eli Lilly made up 0.49% of LGL Partners's portfolio in Q1 2026, its #22 holding.
  • LGL Partners first reported a position in Eli Lilly in Q1 2019 and has held it in 25 quarters since.
  • LGL Partners's Eli Lilly position peaked at $1.8M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on LGL Partners's 13F filing for Q1 2026, filed 14 May 2026.